YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity

por Lam, Wing, Hu, Rong, Liu, Shwu-Huey, Cheng, Peikwen, Cheng, Yung-Chi
Publicado 2023

YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancem...

por Lam, Wing, Arammash, Mohammad, Cai, Wei, Guan, Fulan, Jiang, Zaoli, Liu, Shwu-Huey, Cheng, Peikwen, Cheng, Yung-Chi
Publicado 2023

Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China

por Wu, Jieya, Sun, Baoguo, Hou, Li, Guan, Fulan, Wang, Liyuan, Cheng, Peikwen, Scobell, Sophia, Cheng, Yung-Chi, Lam, Wing
Publicado 2021

YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment

por Yang, Xiaochen, Lam, Wing, Jiang, Zaoli, Guan, Fulan, Han, Xue, Hu, Rong, Cai, Wei, Cheng, William, Liu, Shwu-Huey, Cheng, Peikwen, Cai, Yuping, Rattray, Nicholas J. W., Johnson, Caroline H., Chen, Lieping, Cheng, Yung-Chi
Publicado 2021